What the UK ruling means for patients
The Court of Appeal in London has rejected a challenge aimed at invalidating the UK patent protecting Entresto, Novartis’s best-selling medicine for heart failure. For the hundreds of thousands of British patients who rely on the drug, the immediate effect is continuity of supply — but the longer-term consequences reach deep into NHS budgets and the price British taxpayers pay for treatment. Heart failure is a chronic, life-limiting condition, and the certainty of supply matters as much as the cost to the families who depend on it.
Why the patent matters
Entresto combines two active ingredients, sacubitril and valsartan, into a single pill that has been shown to cut hospitalisations and deaths among people with reduced ejection fraction heart failure. The patent is the legal barrier that, for now, stops rival manufacturers from selling copycat versions at a fraction of the cost. A successful invalidation bid would have opened the door to generic competition almost immediately, mirroring what has already happened in some other markets where the patent has expired and prices have tumbled.
The legal challenge explained
Generic drugmakers had argued that the core patent claims were invalid and should be struck down, a manoeuvre familiar in the pharmaceutical industry wherever a billion-dollar medicine nears the end of its protected life. The court disagreed, finding the Novartis patent enforceable in the UK. The decision mirrors similar rulings elsewhere in Europe, consolidating the company’s position across major markets and signalling to would-be challengers that the UK judiciary will uphold carefully drafted claims.
The cost to the NHS
Heart failure affects more than 900,000 people in the UK, and Entresto is routinely prescribed when older therapies are not enough. Without generic competition, the NHS continues to pay the branded price, which runs into tens of millions of pounds each year. With the health service already under severe financial strain, any delay to cheaper alternatives is felt across the system — potentially squeezing funding for other treatments and adding to the backlog in cardiology clinics where waits are already long.
What patients should know
Clinicians stress that the ruling does not affect the availability or safety of the medicine. Patients should continue taking Entresto exactly as prescribed and speak to their GP or cardiologist before making any changes. The question is purely one of price and competition, not efficacy, and there is no suggestion that supply will be disrupted for the foreseeable future.
The global picture
The UK judgment is one skirmish in a worldwide battle over Entresto’s intellectual property. In the United States, courts have reached mixed conclusions, and in parts of Europe generics have already launched. The divergent outcomes mean patients in different countries face very different prices for the same therapy — a stark illustration of how patent law, not medicine, dictates affordability for ordinary households.
ADVERTISEMENT
What happens next
Novartis has welcomed the decision, which protects a product that remains one of its most important revenue streams. Generic manufacturers may still pursue appeals or wait for the patent’s natural expiry. For now, the UK stays locked into branded pricing — a reminder of how patent law quietly shapes the cost of healthcare for everyone in Britain, and why the debate over drug pricing will not go away.
This article was rewritten for Your News Website from the original Reuters report — read the full story via the source link below.
